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Abstract: Peripheral arterial disease (PAD) is part of a global vascular problem of diffuse 
atherosclerosis. PAD patients die mostly of cardiac and cerebrovascular-related events and 
much less frequently due to obstructive disease of the lower extremities. Aggressive risk factors 
modiﬁ  cation is needed to reduce cardiac mortality in PAD patients. These include smoking 
cessation, reduction of blood pressure to current guidelines, aggressive low density lipoprotein 
lowering, losing weight, controlling diabetes and the use of oral antiplatelet drugs such as aspirin 
or clopidogrel. In addition to quitting smoking and exercise, cilostazol and statins have been 
shown to reduce claudication in patients with PAD. Patients with critical rest limb ischemia 
or severe progressive claudication need to be treated with revascularization to minimize the 
chance of limb loss, reduce symptoms, and improve quality of life.
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Epidemiology of peripheral arterial disease (PAD)
PAD affects 12%–14% of the general population and its prevalence increases with 
age affecting up to 20% of patients over the age of 75 (Hiatt et al 1995). Coexistent 
coronary artery disease (CAD) and cerebrovascular disease (CVD) are highly preva-
lent in patients with PAD particularly in the elderly population. Recent data from 
the Reduction of Atherothrombosis for Continued Health registry presented at the 
American College of Cardiology Annual Scientiﬁ  c Sessions (Bhatt 2005) showed 
that among 7013 patients with symptomatic PAD, polyvascular disease was pres-
ent in 63%. Furthermore, patients over the age of 50 and with PAD in an academic, 
hospital-based geriatric practice have a 68% and 42% incidence of coexistent CAD 
and stroke respectively (Ness and Aronow 1999).
The PAD patients are at an exceptionally high risk for cardiovascular events and 
the majority will eventually die of a cardiac or cerebrovascular etiology. The more 
symptomatic and severe the PAD as objectively measured by the ankle-brachial index 
(ABI), the worse the overall prognosis of the patient. Criqui et al (1992) evaluated 
the association of large-vessel PAD with rates of mortality from all CVD and CAD. 
The relative risk of dying among subjects with large-vessel PAD versus none was 3.1 
(95% CI 1.9–4.9) for deaths from all causes, and 5.9 (95% CI 3.0–11.4) for all deaths 
from cardiovascular disease. Mortality due to cardiovascular disease was 15-fold 
more among symptomatic subjects with severe large-vessel PAD. Finally, PAD has 
been classiﬁ  ed as a coronary heart disease (CHD) risk equivalent, ie, carrying >20% 
risk of a coronary event in 10 years. The Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults (2001) classiﬁ  ed diabetes, multiple 
cardiac risk factors that confer a 10-year risk of >20%, and PAD including carotid 
disease and abdominal aortic aneurysm as a CHD risk equivalent. Vascular Health and Risk Management 2007:3(2) 230
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PAD is very thrombogenic and consists of a large percent-
age of diabetics, hyperlipidemics, and smokers conditions all 
associated with endothelial dysfunction and a hypercoagu-
lable state (Shammas and Dippel 2005). Also, patients with 
PAD have a heightened inﬂ  ammatory state similar to patients 
with unstable angina. In a study by Rossi et al (2002), 51 pa-
tients with symptomatic PAD were followed for 24 months. 
Of these patients 17 (34%) had fatal (11) or non-fatal (6) 
myocardial infarction (MI). Multivariate logistic regression 
analysis showed that only high C-reactive protein (CRP) 
values were signiﬁ  cantly associated with MI (p < 0.05). 
The natural history of PAD indicates that among patients 
with intermittent claudication, 7% will undergo lower ex-
tremity bypass surgery, 4% major amputations, and 16% 
worsening claudication. However, non-fatal cardiovascular 
events (MI, stroke) occur in approximately 20% over a 5-year 
period and the 5-year mortality rate is estimated to be 30% 
(versus 10% in controls), of which 75% were cardiovascular 
deaths (Weitz et al 1996). 
Treatment of the PAD patient has the following goals: 
1) reduce cardiovascular mortality in this high risk popula-
tion, 2) improve quality of life in severe claudicants, and 3) 
lower the chance of amputation in patients with critical limb 
ischemia as manifested by rest limb pain or ulceration.
Classifying the PAD patient
Asymptomatic PAD
Asymptomatic PAD is typically suspected by clinical ex-
amination of the lower extremity pedal pulses. The ABI is a 
simple test that can be conducted in the ofﬁ  ce and typically 
would conﬁ  rm the presence of disease. An ABI is calculated 
by dividing the ankle pressure over the highest brachial pres-
sure. An ABI <0.9 is abnormal and indicates PAD. An ABI 
between 0.7 and 0.9 is considered mild disease, 0.5 and 0.69 
is moderate disease, and less than 0.5 is severe disease. 
Intermittent claudication (IC)
IC is deﬁ  ned as discomfort in the calf muscles with exertion 
that resolves after a few minutes of rest. IC is present in 5% 
of men and 2.5% of women over the age of 60. In a study 
by Jelnes et al (1986) the natural history of 257 patients 
with IC but no rest limb pain were followed for a mean of 
6.5 years. Rest pain or gangrene of the worst affected leg 
was 7.5% in the ﬁ  rst year after referral. Thereafter the rate 
was 2.2% a year. 
Amputation is infrequent in claudicants and occurs in 
5.8% of patients at a mean follow-up of 2.5 years (Imparato 
et al 1975). There are many classiﬁ  cations for claudication 
and limb ischemia but a most utilized one is the Rutherford-
Baker (R-B) classiﬁ  cation (Rutherford et al 1997): R-B I 
indicates essentially asymptomatic patients or symptoms at 
very high level of activity, R-B II is symptoms at moderate 
level of activity, R-B III is symptoms at low level of activity, 
R-B IV is symptoms at rest, R-B V is ulceration, R-B VI is 
ulceration with tissue necrosis. Claudicants are considered in 
the R-B I-III. Typically, endovascular or surgical interven-
tions are reserved for IC Class III and higher.
Chronic limb ischemia 
Chronic limb ischemia (CLI) is pain in the lower extremity 
at rest or ulceration with and without tissue necrosis (R-B IV-
VI). Aggressive treatment of CLI is needed, as progression to 
amputation is frequent. In patients with wound ulcers treated 
without revascularization, a high incidence of amputation 
has been reported particularly in patients with an ABI <0.5. 
Martson et al (2006) reported on the natural history of limb 
ulceration in 142 patients with 169 limbs having ischemic 
limb ulcerations and not surgical candidates because of co-
morbidities or lack of suitable targets for revascularization. 
All ulcers were treated with a protocol emphasizing pressure 
relief, debridement, infection control, and moist wound 
healing. The incidence of diabetes mellitus was 70.4% of 
limbs and chronic renal insufﬁ  ciency 27.8%. Limb loss was 
more prevalent in patients with ABI <0.5 with 28% and 34% 
experiencing limb loss at 6 and 12 months, respectively, 
compared with 10% and 15% of limbs in patients with an 
ABI >0.5 (p = 0.01). Of all limbs included, 23% required 
amputation at 12 months. Overall the primary amputation 
rate in CLI patients is 10%–40% with a mortality rate of 20% 
at 1 year, 40%–70% at 5 years, and 80%–95% at 10 years 
(Dormandy et al 1999).
Acute limb ischemia (ALI)
ALI occurs within hours of presentation and is associated 
with rest limb pain and a pulseless, painful foot. The vessel is 
typically occluded with a thrombus that has occurred on top 
of mild to severe lesions. Collaterals are generally minimal or 
none. ALI occurs because of plaque rupture followed by in situ 
thrombosis or migration of a clot from a proximal location. 
The treatment of ALI is an emergency to save the limb.
Modiﬁ  able risk factors of PAD
Modiﬁ  able risk factors for PAD are not different from pa-
tients with coronary artery disease. Major risk factors include Vascular Health and Risk Management 2007:3(2) 231
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smoking, hyperlipidemia, hypertension, diabetes, and the 
metabolic syndrome. PAD is also more prevalent in males 
and in the elderly. 
Diabetes
Diabetes is one of the strongest predictors for PAD and 
its associated complications including higher mortality 
and amputation; the latter is predicted by the presence of 
neuropathy, retinopathy, low ABI, and male gender. In a 
cross-sectional analysis of a 4153 Greek adults (Athyros 
et al 2004) the odds ratio for vascular disease was 1.94 (95% 
CI 1.35–2.47) for patients with the metabolic syndrome, 3.04 
(95% CI 1.98–4.11) for patients with the metabolic syndrome 
and diabetes, and 1.48 (95% CI 1.12–1.92) for patients with 
the metabolic syndrome but no diabetes. In this study, the 
presence of the metabolic syndrome and diabetes yielded 
a higher risk for PAD then either one alone. Hamalainen 
et al (1999) reported on 733 diabetic patients who were fol-
lowed for 7 years after undergoing podiatric, circulatory, and 
neurophysiological examinations. Amputated patients were 
then compared with patients with no amputations. Using 
multivariate analysis, vibration perception threshold, low 
ABI, history of retinopathy, visual handicap, and male sex 
were independently associated with lower extremity amputa-
tion. Patient education is of paramount importance to reduce 
amputations in the diabetics secondary to foot ulceration.
Smoking 
Smoking is also a powerful risk factor for PAD promoting en-
dothelial dysfunction, and altering lipid metabolism and co-
agulation (Lu and Creager 2004). Price et al (1999) followed 
1592 men and women aged 55–74 years selected at random 
from 11 general practices in Edinburgh, Scotland for 5 years. 
The incidences of PAD and CAD were 5.1% and 11.1%, 
respectively. Cigarette smoking was a stronger risk factor 
for PAD than for CAD. Smoking was associated with an 
increase in coagulation and endothelial dysfunction markers. 
Current smoking of 25 or more cigarettes increased the odds 
ratio of PAD by 7.3 times (95% CI 4.2–12.8). Furthermore, 
current smokers seem to have a higher rate of procedural 
complications following percutaneous interventions. In one 
study (Shammas et al 2003) a total of 131 patients with PAD 
were evaluated for in-hospital predictors of complications 
following percutaneous peripheral intervention (PPI). Forty-
ﬁ  ve patients (34.4%) had recent onset of claudication and 
15 (11.5%) had ulceration. Thrombus was angiographically 
visualized in 16.7% of patients. The best model associated 
with emergent salvage revascularization included cigarette 
smoking within the past year, recent onset of claudication, 
and percutaneous transluminal angioplasty treatment below 
the knee. Smoking was a strong independent predictor of 
the risk for unplanned urgent revascularization of the lower 
extremities following initial successful treatment. 
Dyslipidemia 
Dyslipidemia is also signiﬁ  cant risk factors for PAD. Familial 
hypercholesterolemia increases the prevalence of PAD from 
5-fold to 10-fold compared with non-hypercholesterolemia 
subjects and its treatment with statins reduces the incidence 
of IC and increases walking duration. In a study by Ridker 
et al (2001), the predictive value of 11 lipid and non-lipid 
biomarkers as risk factors for development of PAD was 
compared. Of 14 916 initially healthy US male physicians, 
40–84 years of age, 140 developed symptomatic PAD and 
were age- and smoking-matched to 140 men who remained 
free of vascular disease during an average 9-year follow-
up. Multivariate analysis showed that the total cholesterol-
HDL-C ratio (RR for those in the highest vs lowest quartile, 
3.9; 95% CI 1.7–8.6) and CRP (RR for the highest vs lowest 
quartile, 2.8; 95% CI 1.3–5.9) were the strongest independent 
predictors for development of PAD. The addition of CRP to 
standard lipid screening signiﬁ  cantly improved risk predic-
tion models based on lipid screening alone (p < 0.001).
Obesity 
Obesity is also a signiﬁ  cant risk factor for atherosclerosis 
and PAD. In one study body fat was strongly associated with 
elevated inﬂ  ammation markers including CRP and ﬁ  brino-
gen, which are predictors for active diffuse atherosclerotic 
disease. In a study by Gorter et al (2004) the prevalence 
of the metabolic syndrome in patients with atherosclerotic 
vascular disease was determined in 1117 patients, mean age 
60 years. The prevalence of the metabolic syndrome in the 
study population was 46%: 58% in PAD patients, 41% in 
CHD patients, 43% in CVD patients, and 47% in abdominal 
aortic aneurysm patients. Also Planas et al (2001) have shown 
that the waist-to-hip ratio was independently associated with 
PAD. In a cross-sectional study of 708 men, aged 55–74, 
the relationships between total body fatness (assessed by 
body mass index (BMI)) and abdominal fat distribution (as-
sessed by waist-to-hip ratio) was determined in patients with 
PAD (assessed by ABI). BMI did not correlate with PAD, 
whereas an increased waist-to-hip ratio over the median value 
doubled the prevalence of arterial disease. After controlling Vascular Health and Risk Management 2007:3(2) 232
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for smoking, diabetes, hypertension, high-density lipoprotein 
cholesterol, and triglycerides, increased waist-to-hip ratio 
was independently associated with PAD (OR 1.68; 95% CI 
1.05–2.70).
Hypertension
Lastly, hypertension is also positively associated with PAD 
(Selvin and Erlinger 2004) as shown in the National Health 
and Nutrition Survey (NHANES) data. In this study, 2174 
participants >40 years of age from the 1999–2000 National 
Health and Nutrition Examination Survey were included. 
PAD (ABI <0.9 in either leg) was prevalent in 4.3% of 
patients. Among those >70 years of age, the prevalence was 
14.5%. Current smoking (OR 4.46, 95% CI 2.25–8.84), dia-
betes (OR 2.71, 95% CI 1.03–7.12), hypertension (OR 1.75, 
95% CI 0.97–3.13), hypercholesterolemia (OR 1.68, 95% 
CI 1.09–2.57), and low kidney function (OR 2.00, 95% CI 
1.08–3.70) were positively associated with prevalent PAD. 
In this study, PAD prevalence appears to disproportionately 
affect blacks (OR 2.83, 95% CI 1.48–5.42).
Treatment of patients with PAD
Medical therapies
The focus of PAD treatment is: 1) to reduce symptoms and 
improve quality of life, and 2) to reduce overall cardiovas-
cular morbidity and mortality. 
Smoking cessation 
This an important step to reduce symptoms of claudication and 
the overall burden of cardiovascular complications of athero-
sclerosis (Weitz et al 1996). In a recent study current smoking 
and pack-years of smoking correlate with the presence of PAD 
and smoking cessation for 20 years or more was associated 
with a higher mean ABI and lower prevalence of lower ABI 
(<0.9) than current smokers (Cui et al 2006). Smoking ces-
sation and exercise are considered the two most important 
treatments for PAD (Mukherjee and Yadav 2001). 
Exercise 
Exercise has also been shown to improve symptoms of clau-
dication and prolong pain-free walking time and distance and 
improve peak oxygen consumption. Exercise needs to be 
performed regularly with beneﬁ  t becomes noticeable in few 
months. The exact mechanism by which exercise contributes 
to improvement in walking distance is unclear. Exercise, 
however, reduced resting plasma short-chain acylcarnitine 
(associated with functional impairment of PAD patients) by 
26% that correlated with improvement in peak walking time 
(r = –0.78, p less than 0.05) (Hiatt et al 1990). In a random-
ized study by Hiatt et al (1990) 19 patients with disabling 
claudication were randomized to exercise (supervised tread-
mill walking [1 hour/day, 3 days/week, for 12 weeks] with 
progressive increases in speed and grade as tolerated) and 
compared with a control group. Exercise subjects increased 
their peak walking time 123%, peak oxygen consump-
tion 30%, and pain-free walking time 165% (all p < 0.05). 
Control subjects had no change in peak oxygen consump-
tion, but after 12 weeks, peak walking time increased 20% 
(p < 0.05). Exercise is an important therapeutic recommenda-
tion to patients with PAD (Mukherjee and Yadav 2001).
Cilostazol 
This pharmacological agent also has been shown to increase 
walking distance after 24 weeks of treatment by a mean 54% 
from baseline compared with placebo or pentoxifylline. In 
a double-blind, placebo-controlled, multicenter, randomized 
trial by Dawson et al (2000) to evaluate the relative efﬁ  cacy 
and safety of cilostazol and pentoxifylline, 698 patients were 
randomly assigned to blinded treatment with either cilostazol 
(100 mg orally twice a day), pentoxifylline (400 mg orally 3 
times a day), or placebo. The primary endpoint was walking 
distance with constant-speed, variable-grade treadmill testing 
at baseline and at 4, 8, 12, 16, 20, and 24 weeks. The improve-
ment with pentoxifylline was similar (p = 0.82) to that in the 
placebo group whereas cilostazol increased walking distance 
by 54% from baseline. Cilostazol has multiple pharmacologic 
actions including reduction in platelet aggregation, vasodila-
tation and improving lipid proﬁ  le (Schror 2002) 
Statins
Statins have also been shown to reduce claudication and 
increase walking distance by 24% at 6 months and 42% at 
1 year compared with placebo. Statins are also essential to 
reduce cardiovascular events in patients with atherosclerotic 
disease irrespective of lipid levels. Aronow et al (2003) 
has found that simvastatin signiﬁ  cantly increased treadmill 
exercise time until onset of claudication by 24% (p < 0.0001) 
at 6 months and 42% (p < 0.0001) at 1 year after treatment 
with no change in these parameters in the control group. 
Furthermore, in a study by Mondillo et al (2003), high-dose 
(40 mg/day) short-term therapy with simvastatin in 43 patients 
with symptomatic PAD and a total cholesterol >220 mg/dL 
improved walking performance (mean 126 m improvement 
in distance; 95% CI 101–151 m; p < 0.001), ankle-brachial Vascular Health and Risk Management 2007:3(2) 233
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pressure indices (mean, 0.09; 95% CI 0.06–0.12; p < 0.01), 
and symptoms of claudication compared with a control group 
of 43 patients receiving placebo. Statins are important drugs 
to reduce cardiovascular events in patients with documented 
vascular disease and therefore a low threshold to use these 
drugs in patients with PAD is warranted.
Antithrombotic therapy (aspirin or ADP-
receptor antagonists clopidogrel or 
ticlopidine) 
Antithrombotic therapy has not been shown to improve 
symptoms of claudication but is important to reduce car-
diovascular complications associated with the presence of 
atherosclerosis and PAD. The Antithrombotic Trialist Col-
laboration (2002) showed that a low dose aspirin (75–150 
mg) reduces vascular events by 32% in the high-risk patient 
including the subset of patients with PAD (p = 0.004). In 
this meta-analysis  of 287 randomized trials involving 135 
000 patients in comparisons of antiplatelet therapy versus 
control and 77 000 in comparisons of different antiplatelet 
regimens among each others in high risk patients (with acute 
or previous vascular disease or some other predisposing 
condition), “serious vascular event” including non-fatal 
MI, non-fatal stroke, or vascular death were reduced in the 
antiplatelet group. In addition, in the Clopidogrel versus 
Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) 
trial (CAPRIE 1996), the long-term administration of 
clopidogrel to patients with atherosclerotic vascular disease 
(follow-up for 1–3 years) was more effective than aspirin 
in reducing the combined risk of ischemic stroke, MI, or 
vascular death (5.83% versus 5.32% for aspirin versus 
clopidogrel respectively, p = 0.045). 
Ticlopidine also has protective effects probably similar to 
clopidogrel in the high-risk vascular patient but its adverse 
side-effects have limited its use. The long-term use of the 
clopidogrel-aspirin combination compared with aspirin alone 
was recently published in the Clopidogrel and Aspirin versus 
Aspirin alone for the Prevention of Atherothrombotic Events 
(CHARISMA) trial (Bhatt et al 2006). The CHARISMA trial 
has enrolled 15 603 patients with established CAD, CVD, 
or PAD, or at high risk of developing atherothrombosis due 
to multiple risk factors. These patients were randomized to 
receive either clopidogrel or placebo, in addition to low- to 
moderate-dose aspirin. The rate of the primary efﬁ  cacy end 
point was 6.8% with clopidogrel plus aspirin and 7.3% with 
placebo plus aspirin (RR 0.93; 95% CI 0.83–1.05; p = 0.22). 
Clopidogrel added to aspirin was not signiﬁ  cantly more 
effective than aspirin alone in reducing the rate of myocardial 
infarction, stroke, or death from cardiovascular causes. In the 
subgroup of patients with documented vascular disease, the 
rate was 6.9% with clopidogrel and 7.9% with placebo (RR 
0.88; 95% CI 0.77–0.998; p = 0.046). There was a suggestion 
of beneﬁ  t with clopidogrel treatment in patients with symp-
tomatic atherosclerotic vascular disease and a suggestion of 
harm in patients with multiple risk factors but no documented 
atherosclerosis. Currently clopidogrel alone or aspirin alone 
are strongly recommended in patients with PAD. Patients, 
however, with a recent acute coronary syndrome will beneﬁ  t 
from the combination of aspirin and clopidogrel for at least 
1 year after the event (CURE 2001).
Revascularization therapies
Revascularization is indicated for the relief of ischemic 
symptoms, particularly when medical therapy fails or is 
insufﬁ  cient. There are two primary goals of revasculariza-
tion: ﬁ  rst, to relieve symptom-limiting claudication or rest 
ischemic pain; second, to minimize tissue loss or limit the 
degree of amputation.
Over the past decade there has been an exponential rise 
in lower extremity PPI with a concomitant drop in surgical 
interventions (Anderson et al 2004). Most patients with ad-
vanced PAD have occult or symptomatic coronary/cerebral 
vascular disease, and thus the mortality of peripheral bypass 
surgery may exceed 10% in high-risk patients (Dormandy 
and Rutherford 2000).
Minimally invasive endovascular therapy offers inher-
ent advantages over traditional surgical revascularization, 
such as lower morbidity, shorter hospital length of stay, and 
considerably less patient discomfort. As the ﬁ  eld of endo-
vascular therapy continues to grow, the need for traditional 
surgical therapies will be considerably reduced. The discus-
sion of revascularization techniques is beyond the scope of 
this manuscript. 
In summary, PAD is a part of a diffuse atherosclerotic 
problem and a marker of cardiac and cerebrovascular mortal-
ity. Initial therapy is preventive for all patients with a focus 
on aggressively controlling modiﬁ  able traditional risk factors 
for coronary artery disease and PAD. Smoking cessation, 
controlling elevated blood pressure and blood glucose, los-
ing excess body fat, exercise, treating hyperlipidemia with 
statins, and the use of antiplatelets are crucial ﬁ  rst steps in 
the management of the PAD patient. Revascularization is 
reserved for the very symptomatic patient or those with 
critical limb ischemia.Vascular Health and Risk Management 2007:3(2) 234
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